GlassScriptPhysician profile
Giorgio A Roccaro
NPI 1205121985
$12,869.25
in general payments reported to CMS, 2019-2025
8 companies · $8,306 in 2025
The $8,306 reported for 2025 was more than what 77% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,400 · 2024: $2,163 · 2025: $8,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,868 · Travel and Lodging: $2,332 · Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,867.50 |
| Travel and Lodging | $2,332.48 |
| Food and Beverage | $1,269.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $7,435.53 | 2024-2025 | Utaswako Afp-L3 |
| Biomarin Pharmaceutical INC. | $2,400.00 | 2021 | |
| Transmedics, INC. | $2,332.48 | 2025 | Organ Care System |
| Gilead Sciences, INC. | $296.07 | 2025 | |
| Boston Scientific Corporation | $164.42 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Madrigal Pharmaceuticals | $112.34 | 2025 | Rezdiffra |
| Mirum Pharmaceuticals, INC. | $103.44 | 2025 | Livmarli |
| Astrazeneca Pharmaceuticals LP | $24.97 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giorgio Roccaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.